Healthcare Equipment and Supplies
Company Overview of R-Biopharm AG
R-Biopharm AG develops test solutions for clinical diagnostics, and food and feed analysis. It offers test systems for applications in the fields of infectological stool, serological infection, and allergy diagnostics; test systems for antibody and antigen detections, delayed food allergy diagnostics, gastroenterology, histamine release detections, and molecular and vitamin diagnostics; and accessories, such as pipets and stool collectors. The company also provides RIDA SOFT Win.net, a software solution for evaluating enzyme immunoassays; RIDA SMART APP Mycotoxin, an evaluation technology for the quantification of aflatoxin in corn; and other related software solutions. In addition, it offer...
An der neuen Bergstraße 17
Founded in 1988
Key Executives for R-Biopharm AG
Chief Executive Officer and Managing Director
Compensation as of Fiscal Year 2016.
R-Biopharm AG Key Developments
R-Biopharm AG to Collaborate with HMNC Brain Health on Complementary Diagnostic Test for Optimization of Depression Treatment
Apr 19 16
R-Biopharm AG announced that it has entered into a collaboration agreement with HMNC Brain Health in the field of complementary diagnostics. Under this agreement R-Biopharm AG will develop an in vitro PCR (Polymerase Chain Reaction) based genetic test. The goal is to identify ABCB1 gene variants in patients who are treated with antidepressants in order to optimize the efficacy of depression therapy. The collaboration includes the development, regulatory approval, manufacturing and commercialization of the ABCB1 test.
R-Biopharm AG Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
R-Biopharm AG Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101
Jul 28 15
Apogenix announced that it has entered into an agreement with R-Biopharm to develop companion diagnostic tests for Apogenix' lead drug candidate APG101. APG101 is a CD95 ligand inhibitor which restores the body's immune response against tumors and inhibits invasive tumor cell growth. The drug candidate is being developed for the treatment of solid tumors and malignant hematological diseases. In a controlled phase II efficacy trial in patients with recurrent glioblastoma, treatment with APG101 in combination with radiotherapy has demonstrated clinical superiority in all study endpoints compared to treatment with radiotherapy alone. Glioblastoma patients with a certain biomarker associated with the CD95 ligand experienced the great benefit from treatment with APG101. The trial showed a statistically significant prolongation of overall survival in biomarker-positive patients treated with APG101, with a median overall survival of 16.1 months compared to 7.3 months in patients treated with radiotherapy alone. Based on different test technologies including immunohistochemistry (IHC) and polymerase chain reaction (PCR), Apogenix and R-Biopharm will develop patient-stratifying companion diagnostic tests to identify glioblastoma patients who are most likely to benefit from treatment with APG101. The cooperation further includes the development of in vitro diagnostic tests to determine expression of the CD95 ligand in other types of tumors. Apogenix will validate the resulting diagnostic tests in a pivotal phase II/III trial in glioblastoma and in additional clinical trials for the treatment of other solid tumors. These diagnostic tests will allow to develop APG101 as a targeted therapy for the treatment of cancer, so patients can benefit from a personalised treatment approach.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries